- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00368407
Optimal Treatment Frequency of 308-Nm Excimer Laser for Vitiligo on the Face and Neck
August 23, 2006 updated by: Air Force Military Medical University, China
To determine the optimal treatment frequency of 308-nm excimer laser for vitiligo and identify the key clinical variable(s) associated with the treatment efficiency under the optimal treatment frequency.
Prospective, randomized, comparative study among groups of vitiligo patients treated with 308-nm excimer laser, with the limitation of no follow-up.
Study Overview
Detailed Description
Vitiligo patients were treated with 308-nm excimer laser for 20 sessions at different frequencies (0.5×, 1.0×, 2.0× and 3.0× weekly).
Treatment protocols adapted the dose to the lesions and not to the minimal erythemal dose.
Treatment efficacy was blindly evaluated by 2 independent physicians.
Re-pigmentation rate was graded on a 6-point scale.
The onset of re-pigmentation of vitiligo lesions was evaluated after 5 treatment sessions.
The differences between Group 0.5×, 1.0×, 2.0× and 3.0× linking different clinical variables were assessed.
Study Type
Observational
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
SHANNXI
-
Xi'an, SHANNXI, China, 710032
- Department of dermatology, Xijing Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 60 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- older than 2 years, stable vitiliginous patches during the past 3 months with surfaces of at least 4cm2, and an understanding of all information given by signing a written consent form.
Exclusion Criteria:
- pregnant or breastfeeding women; personal history of a hypertrophic scar, skin cancer; taking immunosuppressive or photosensitizing drugs and undergoing phototherapy during the past 3 months.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Time Perspectives: Prospective
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: gao tianwen, MD,PHD, Ddepartment of Dermatology
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2005
Study Completion
July 1, 2006
Study Registration Dates
First Submitted
August 23, 2006
First Submitted That Met QC Criteria
August 23, 2006
First Posted (Estimate)
August 24, 2006
Study Record Updates
Last Update Posted (Estimate)
August 24, 2006
Last Update Submitted That Met QC Criteria
August 23, 2006
Last Verified
April 1, 2005
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- fmmu200504
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitiligo
-
PfizerRecruitingStable Nonsegmental Vitiligo | Active Nonsegmental VitiligoUnited States, Spain, Australia, Mexico, Canada, China, Japan, Italy, Turkey, Korea, Republic of, Germany, South Africa, Poland, United Kingdom, Bulgaria
-
PfizerRecruitingStable Nonsegmental Vitiligo | Active Nonsegmental VitiligoJapan, Canada, China, United States
-
Fundació Institut de Recerca de l'Hospital de la...Completed
-
Incyte CorporationRecruitingNonSegmental VitiligoGermany, United States, Italy, Poland, Canada, France, Bulgaria, Hungary, United Kingdom
-
Incyte CorporationCompletedNonSegmental VitiligoUnited States, Canada
-
Cairo UniversitySuspended
-
Assiut UniversityUnknown
-
University of TorontoCanadian Interdisciplinary Network Complementary & Alternative Medicine ResearchCompleted
-
University Hospital, GhentNovartisCompletedVitiligo VulgarisBelgium
Clinical Trials on 308-nm excimer laser
-
Chulalongkorn UniversityRatchadapiseksompotch FundUnknownLichen AmyloidosisThailand
-
The Catholic University of KoreaUnknownVitiligoKorea, Republic of
-
University of UtahAmerican Society for Dermatologic SurgeryCompleted
-
The Catholic University of KoreaUnknownRecurrence | Vitiligo | Maintenance Therapy | the 308-nm Excimer LaserKorea, Republic of
-
Phoenix Children's HospitalWithdrawn
-
Ra Medical SystemsCompletedPeripheral Arterial DiseaseUnited States
-
Instituto Vascular BHCompleted
-
Durrie VisionAlcon ResearchUnknown
-
College of CharlestonCompletedMuscle FatigueUnited States